Skip to main content
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. — Investor Relations & Filings

Ticker · NRSN ISIN · IL0011809592 LEI · 254900UWMHXRH1IZPT20 US Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2026-06-08 Regulatory Filings
Country IL Israel
Listing US NRSN

About NeuroSense Therapeutics Ltd.

https://www.neurosense-tx.com/

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 92% confidence The document is a Form 6-K “Report of Foreign Private Issuer” under the Exchange Act, containing an update on a regulatory meeting with Health Canada and no substantive financial statements or proxy materials. It is a routine SEC regulatory filing rather than a full annual report, earnings release, or specialized category. Therefore, this falls under the general Regulatory Filings (RNS) category.
2026-06-08 English
6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes an explanatory note about a press release regarding a PIPE financing pricing. The document is short (2210 characters) and primarily serves to furnish a press release as Exhibit 99.1. There are no financial statements or detailed financial data included. The document is an announcement of a financing event and the filing of a report, not a full financial report or earnings release. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it does not fit into more specific categories and is a general regulatory announcement.
2026-04-28 English
6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It announces a management change, specifically the stepping down of the Chief Medical Officer and his transition to an advisory role. The content focuses on board/management information rather than financial results, audit, or other report types. The document length is short (2168 characters) and contains no financial statements or detailed financial data. Therefore, it fits the category of Board/Management Information (MANG).
2026-04-24 English
6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes an explanatory note about a press release regarding a patent grant and references to registration statements. The document is short (2290 characters) and primarily serves to furnish a press release rather than containing detailed financial data or comprehensive reports. It does not contain financial statements or detailed management discussion. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-04-06 English
6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes an explanatory note about a press release regarding Nasdaq notifications on minimum bid price and market value requirements. The document is short (2342 characters) and primarily serves to furnish a press release as Exhibit 99.1. There are no financial statements or detailed financial data present. The document is an announcement/report filing rather than a full financial report or earnings release. According to the rules, such filings that do not fit other categories and are regulatory announcements fall under Regulatory Filings (RNS).
2026-04-03 English
6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release dated March 31, 2026, reporting year-end 2025 financial results and business updates. The document length is 1775 characters, which is relatively short and primarily serves to furnish the press release rather than containing detailed financial statements or comprehensive analysis. According to the 'Menu vs Meal' rule, short documents that provide a press release or announcement of financial results without detailed financial data should be classified as Regulatory Filings (RNS). Therefore, this document is best classified as a Regulatory Filing (RNS).
2026-03-31 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.